Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia
The randomized, Phase 2, double-blind, placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD
Rejuvenate Biomed, the NIHR Leicester BRC, and Wellcome Leap partner for Phase 2 Study in COPD-related sarcopenia
The Phase 2 double-blind placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD. Rejuvenate Biomed anticipates commencing patient enrollment first half 2025
Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools
Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools
Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia
Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia.
Positive results Phase 1b trial in sarcopenia
Primary and secondary endpoints have been met in this placebo-controlled study in disuse-induced muscle atrophy. RJx-01 was safe and well tolerated and the innovative formulation confirmed excellent pharmacokinetics.